Omnicell, Inc. (OMCL) Expected to Announce Quarterly Sales of $177.37 Million

Wall Street analysts predict that Omnicell, Inc. (NASDAQ:OMCL) will post sales of $177.37 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Omnicell’s earnings, with the lowest sales estimate coming in at $177.32 million and the highest estimate coming in at $177.41 million. Omnicell reported sales of $150.55 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 17.8%. The firm is scheduled to report its next earnings results on Thursday, May 3rd.

According to Zacks, analysts expect that Omnicell will report full-year sales of $177.37 million for the current financial year, with estimates ranging from $788.21 million to $790.51 million. For the next year, analysts expect that the firm will post sales of $879.58 million per share, with estimates ranging from $867.46 million to $898.15 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Omnicell.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.02. The company had revenue of $198.26 million for the quarter, compared to analyst estimates of $205.50 million. Omnicell had a return on equity of 1.54% and a net margin of 2.88%. The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.37 earnings per share.

Several brokerages have issued reports on OMCL. Zacks Investment Research lowered Omnicell from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $63.00 price objective on shares of Omnicell in a report on Thursday, February 1st. Oppenheimer reaffirmed a “buy” rating and set a $55.00 price objective on shares of Omnicell in a report on Tuesday, December 5th. Craig Hallum lowered Omnicell from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Piper Jaffray Companies raised their price objective on Omnicell from $38.00 to $44.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. Omnicell presently has an average rating of “Hold” and an average price target of $56.14.

In related news, VP Peter J. Kuipers sold 4,724 shares of the firm’s stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $47.74, for a total transaction of $225,523.76. Following the transaction, the vice president now owns 40,544 shares of the company’s stock, valued at $1,935,570.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Peter J. Kuipers sold 1,926 shares of the firm’s stock in a transaction dated Monday, December 18th. The stock was sold at an average price of $51.69, for a total value of $99,554.94. Following the transaction, the chief financial officer now directly owns 40,544 shares in the company, valued at approximately $2,095,719.36. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,263 shares of company stock worth $1,023,726. Corporate insiders own 3.77% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. grew its holdings in shares of Omnicell by 4.0% during the fourth quarter. BlackRock Inc. now owns 4,839,191 shares of the company’s stock worth $234,701,000 after buying an additional 187,069 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Omnicell by 3.7% during the second quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock worth $83,105,000 after buying an additional 67,902 shares during the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of Omnicell by 10.8% during the fourth quarter. Conestoga Capital Advisors LLC now owns 1,792,313 shares of the company’s stock worth $86,927,000 after buying an additional 174,607 shares during the last quarter. Eagle Asset Management Inc. grew its holdings in shares of Omnicell by 36.8% during the fourth quarter. Eagle Asset Management Inc. now owns 1,365,794 shares of the company’s stock worth $66,047,000 after buying an additional 367,687 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Omnicell by 129.6% during the second quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock worth $53,096,000 after buying an additional 695,334 shares during the last quarter.

Omnicell (NASDAQ OMCL) opened at $41.00 on Friday. The stock has a market capitalization of $1,555.21, a PE ratio of 80.39, a price-to-earnings-growth ratio of 3.38 and a beta of 0.65. Omnicell has a twelve month low of $35.00 and a twelve month high of $55.40. The company has a current ratio of 1.73, a quick ratio of 1.28 and a debt-to-equity ratio of 0.38.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/11/omnicell-inc-omcl-expected-to-announce-quarterly-sales-of-177-37-million.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply